Trial Design: Human papillomavirus infection causes verruca vulgaris. CDK9 inhibitor FIT039 inhibits DNA virus proliferation in animal models. We conducted a multicenter, single-blind, placebo-controlled, randomized phase I/II clinical trial evaluating the safety and efficacy of FIT039 against verruca vulgaris.
Methods: Target lesions were treated with liquid nitrogen once, and a FIT039 patch or placebo patch was applied for 14 days. The primary endpoint was lesion disappearance. The secondary endpoints were safety and changes in dimension, cross-sectional area, and the number of petechial lesions.
Results: A total of 24 participants were randomly allocated to the FIT039 (n = 13, median age, 54 years) and placebo (n = 11, median age, 62 years) groups. Verruca vulgaris did not disappear. FIT039 decreased the dimension to 76% of the initial value on day 29, followed by an increase to 98% on day 57. Placebo showed a monotonic increase to 107% on day 57. Changes in the cross-sectional area and petechiae number were comparable between the groups.
Conclusions: No drug-related adverse reactions occurred. FIT039 efficacy was not determined in this study.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659400 | PMC |
| http://dx.doi.org/10.1016/j.xjidi.2021.100026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful pregnancy outcome in a recipient of simultaneous pancreatic kidney transplantation.
BMJ Case Rep
January 2025
Obstetrics and Gynecology, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India.
There is limited information available regarding post-simultaneous pancreatic kidney transplantation (SPKT) pregnancies. The present case describes a woman in her early 30s with first pregnancy who conceived spontaneously 4 years after SPKT. Her pancreatic and kidney graft function remained stable throughout the pregnancy.
View Article and Find Full Text PDFStevens-Johnson induced by imiquimod 5% cream: a case report.
Dermatol Reports
November 2024
Department of Dermatology, Dipartimento della Salute (DiSSal), University of Genoa; IRCCS, Ospedale Policlinico San Martino, Genoa, Italy.
Imiquimod 5% cream is an approved treatment for actinic keratoses, superficial basal cell carcinomas, and anogenital warts. Severe systemic side effects associated with imiquimod 5% cream are rare, although a few cases of erythema multiforme and Stevens-Johnson syndrome have been described. We present a case of Stevens-Johnson syndrome associated with topical treatment with imiquimod of two superficial basal cell carcinomas.
View Article and Find Full Text PDFModified intralesional acyclovir therapy in the management of recalcitrant palmoplantar and ungual warts: a case series of 14 patients.
Clin Exp Dermatol
January 2025
Department of Dermatology, IMS and SUM Hospital, Bhubaneswar, India.
This study evaluated the efficacy and safety of Intralesional Acyclovir in the treatment of recalcitrant palmoplantar and ungual warts in 14 patients(7 male and 7 female) of mean age 24.5 +- 8.19 years.
View Article and Find Full Text PDFFGFR3 Upregulates Interferon-Stimulated Genes Via the JAK1-STAT1 Signaling Pathway in HPV2 E2 Stable Expressing Keratinocytes.
J Med Virol
January 2025
Department of Dermatology, First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China.
Human papillomavirus (HPV) infections are prevalent skin infectious diseases. While there are no specific anti-HPV drugs available, understanding the viral mechanisms could lead to novel therapeutic strategies. Verruca vulgaris, a common HPV infection, is frequently encountered in dermatological clinics.
View Article and Find Full Text PDFComments on the increased risk of hidradenitis suppurativa in patients with human papillomavirus infection.
J Am Acad Dermatol
December 2024
Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Dermatology, National Yang Ming Chao Tung University, Taipei, Taiwan; School of Medicine, National Yang Ming Chao Tung University, Taipei, Taiwan. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!